Completed PHASE4 INTERVENTIONAL 2-arm NCT05118399

Analgesic Effect of Liposomal Bupivacaine

Addition of Liposomal Bupivacaine to Standard Bupivacaine Versus Standard Bupivacaine Alone in the Supraclavicular Brachial Plexus Block: a Randomized Controlled Trial

Sponsor: The University of Hong Kong

Conditions Acute Pain

Interventions Bupivacaine Injection [Marcaine] Bupivacaine Liposome 13.3 MG/ML [Exparel]

Updated 7 times since 2021 Last updated: Jan 12, 2024 Started: Nov 15, 2021 Primary completion: Dec 8, 2022 Completion: Mar 8, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Acute Pain and is currently completed. The University of Hong Kong leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Feb 2024 — Jul 2024 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Aug 2023 — Feb 2024 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Jan 2022 — Jun 2023 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Dec 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The University of Hong Kong

Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, Hong Kong